{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T14:39:17Z","timestamp":1794667157087,"version":"4.9.1"},"reference-count":60,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"40","license":[{"start":{"date-parts":[[2021,10,8]],"date-time":"2021-10-08T00:00:00Z","timestamp":1633651200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"u.s. president's emergency plan for aids relief","award":["no"],"award-info":[{"award-number":["no"]}]},{"name":"clinton health access initiative","award":["no"],"award-info":[{"award-number":["no"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>An estimated 1.5 million Kenyans are HIV-seropositive, with 1.1 million on antiretroviral therapy (ART), with the majority of them unaware of their drug resistance status. In this study, we assessed the prevalence of drug resistance to nucleoside reverse transcriptase inhibitors (NRTIs), nucleoside reverse transcriptase inhibitors (NNRTIs), and protease inhibitors, and the variables associated with drug resistance in patients failing treatment in Nairobi, Kenya.<\/jats:p>\n            <jats:p>This cross-sectional study utilized 128 HIV-positive plasma samples obtained from patients enrolled for routine viral monitoring in Nairobi clinics between 2015 and 2017. The primary outcome was human immunodeficiency virus type 1 (HIV-1) drug resistance mutation counts determined by Sanger sequencing of the polymerase <jats:italic toggle=\"yes\">(pol)<\/jats:italic> gene followed by interpretation using Stanford's HIV Drug Resistance Database. Poisson regression was used to determine the effects of sex, viral load, age, HIV-subtype, treatment duration, and ART-regimen on the primary outcome.<\/jats:p>\n            <jats:p>HIV-1 drug resistance mutations were found in 82.3% of the subjects, with 15.3% of subjects having triple-class ART resistance and 45.2% having dual-class resistance. NRTI primary mutations M184\u200aV\/I and K65R\/E\/N were found in 28.8% and 8.9% of subjects respectively, while NNRTI primary mutations K103N\/S, G190A, and Y181C were found in 21.0%, 14.6%, and 10.9% of subjects. We found statistically significant evidence (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.013) that the association between treatment duration and drug resistance mutations differed by sex. An increase of one natural-log transformed viral load unit was associated with 11% increase in drug resistance mutation counts (incidence rate ratio [IRR] 1.11; 95% CI 1.06\u20131.16; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.001) after adjusting for age, HIV-1 subtype, and the sex-treatment duration interaction. Subjects who had been on treatment for 31 to 60\u200amonths had 63% higher resistance mutation counts (IRR 1.63; 95% CI 1.12\u20132.43; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.013) compared to the reference group (&lt;30\u200amonths). Similarly, patients on ART for 61 to 90\u200amonths were associated with 133% higher mutation counts than the reference group (IRR 2.33; 95% CI 1.59\u20133.49; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.001). HIV-1 subtype, age, or ART-regimen were not associated with resistance mutation counts.<\/jats:p>\n            <jats:p>Drug resistance mutations were found in alarmingly high numbers, and they were associated with viral load and treatment time. This finding emphasizes the importance of targeted resistance monitoring as a tool for addressing the problem.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000027460","type":"journal-article","created":{"date-parts":[[2021,10,8]],"date-time":"2021-10-08T13:31:11Z","timestamp":1633699871000},"page":"e27460","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":22,"title":["Prevalence and factors associated with HIV-1 drug resistance mutations in treatment-experienced patients in Nairobi, Kenya"],"prefix":"10.1097","volume":"100","author":[{"given":"Yvonne A.","family":"Scriven","sequence":"first","affiliation":[{"name":"Centre for Infectious and Parasitic Diseases Control Research, Kenya Medical Research Institute, Busia, Kenya"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9613-5425","authenticated-orcid":false,"given":"Martin M.","family":"Mulinge","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, School of Medicine, University of Nairobi, Nairobi, Kenya"},{"name":"Kenya AIDS Vaccine Initiative - Institute of Clinical Research, University of Nairobi, Nairobi, Kenya."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norah","family":"Saleri","sequence":"additional","affiliation":[{"name":"Centre for Infectious and Parasitic Diseases Control Research, Kenya Medical Research Institute, Busia, Kenya"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Luvai","sequence":"additional","affiliation":[{"name":"Centre for Infectious and Parasitic Diseases Control Research, Kenya Medical Research Institute, Busia, Kenya"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atunga","family":"Nyachieo","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, School of Medicine, University of Nairobi, Nairobi, Kenya"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther N.","family":"Maina","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, School of Medicine, University of Nairobi, Nairobi, Kenya"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matilu","family":"Mwau","sequence":"additional","affiliation":[{"name":"Centre for Infectious and Parasitic Diseases Control Research, Kenya Medical Research Institute, Busia, Kenya"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,10,8]]},"reference":[{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1128\/CMR.15.2.247-277.2002","article-title":"Genotypic testing for human immunodeficiency virus type 1 drug resistance","volume":"15","author":"Shafer","year":"2002","journal-title":"Clin Microbiol Rev"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"09","DOI":"10.1186\/1742-6405-11-9","article-title":"HIV-1 virologic failure and acquired drug resistance among first-line antiretroviral experienced adults at a rural HIV clinic in coastal Kenya: a cross-sectional study","volume":"11","author":"Hassan","year":"2014","journal-title":"AIDS Res Ther"},{"key":"R5-20250504","year":"2018","journal-title":"Guideline on Use of Antiretroviral Drugs for Treating and Preventing HIV in Kenya"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"01","DOI":"10.1371\/journal.pone.0190659","article-title":"Scale-up of Kenya's national HIV viral load program: findings and lessons learned","volume":"13","author":"Mwau","year":"2018","journal-title":"PLoS One"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"02","DOI":"10.1371\/journal.pone.0171124","article-title":"Surveillance of HIV-1 pol transmitted drug resistance in acutely and recently infected antiretroviral drug-na\u00efve persons in rural western Kenya","volume":"12","author":"Onywera","year":"2017","journal-title":"PLoS One"},{"key":"R9-20250504","first-page":"01","article-title":"HIV-1 Genotyping Workflow","year":"2017","journal-title":"Thermo Fish Sci"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1128\/JCM.06689-11","article-title":"Automating HIV drug resistance genotyping with RECall, a freely accessible sequence analysis tool","volume":"50","author":"Woods","year":"2012","journal-title":"J Clin Microbiol"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.chom.2012.07.005","article-title":"As good as it gets? the problem of HIV persistence despite antiretroviral drugs","volume":"12","author":"Sigal","year":"2012","journal-title":"Cell Host Microbe"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1086\/375597","article-title":"Antiretroviral drug resistance testing in adults infected with human immunodefidency virus type 1: 2003 Recommendations of an International Aids Society-USA panel","volume":"37","author":"Hirsch","year":"2003","journal-title":"Clin Infect Dis"},{"key":"R13-20250504","first-page":"180","article-title":"HIV drug resistance","volume":"350","author":"Clavel","year":"2016","journal-title":"Front HIV Res"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1016\/S0140-6736(03)15022-2","article-title":"Treatment of antiretroviral-drug-resistant HIV-1 infection","volume":"362","author":"Deeks","year":"2003","journal-title":"Lancet"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0140-6736(04)16589-6","article-title":"Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes","volume":"364","author":"Ledergerber","year":"2004","journal-title":"Lancet"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1128\/AAC.04215-14","article-title":"Impact of drug resistance-associated amino acid changes in HIV-1 subtype C on susceptibility to newer nonnucleoside reverse transcriptase inhibitors","volume":"59","author":"Basson","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"e72152","DOI":"10.1371\/journal.pone.0072152","article-title":"High-levels of acquired drug resistance in adult patients failing first-line antiretroviral therapy in a rural HIV treatment programme in KwaZulu-Natal, South Africa","volume":"8","author":"Manasa","year":"2013","journal-title":"PLoS One"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"02","DOI":"10.1186\/s12981-020-0258-7","article-title":"Comparison of HIV drug resistance profiles across HIV-1 subtypes A and D for patients receiving a tenofovir-based and zidovudine-based first line regimens in Uganda","volume":"17","author":"Ayitewala","year":"2020","journal-title":"AIDS Res Ther"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1097\/QAD.0b013e32832ac34e","article-title":"The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy","volume":"23","author":"Hosseinipour","year":"2009","journal-title":"Aids"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1097\/QAD.0b013e32835b0f59","article-title":"Tenofovir-based regimens associated with less drug resistance in HIV-1-infected Nigerians failing first-line antiretroviral therapy","volume":"27","author":"Etiebet","year":"2013","journal-title":"Aids"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1310\/hct0803-164","article-title":"The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6\u200ayears in antiretroviral-na\u00efve HIV-1-infected patients","volume":"8","author":"Cassetti","year":"2007","journal-title":"HIV Clin Trials"},{"key":"R23-20250504","first-page":"1000239","article-title":"Pre-treatment HIV-drug resistance associated with virologic outcome of first-line NNRTI-antiretroviral therapy: a cohort study in Kenya","volume":"18","author":"Beck","year":"2020","journal-title":"SSRN Electron J"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/00002030-200001280-00012","article-title":"HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy","volume":"14","author":"Miller","year":"2000","journal-title":"Aids"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"17355","DOI":"10.1073\/pnas.0607274103","article-title":"Genotypic predictors of human immunodeficiency virus type 1 drug resistance","volume":"103","author":"Rhee","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"01","DOI":"10.1186\/s12981-016-0128-5","article-title":"Early virological failure and HIV drug resistance in Ugandan adults co-infected with tuberculosis","volume":"14","author":"Braun","year":"2017","journal-title":"AIDS Res Ther"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1086\/378281","article-title":"Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates","volume":"188","author":"Whitcomb","year":"2003","journal-title":"J Infect Dis"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0140-6736(11)60936-7","article-title":"Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial","volume":"378","author":"Molina","year":"2011","journal-title":"Lancet"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S1473-3099(15)00536-8","article-title":"Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study","volume":"16","author":"Gregson","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1177\/135965350501000705","article-title":"Thymidine analogue mutation profiles: Factors associated with acquiring specific profiles and their impact on the virological response to therapy","volume":"10","author":"Cozzi-Lepri","year":"2005","journal-title":"Antivir Ther"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1093\/cid\/cix1108","article-title":"Effectiveness of protease inhibitor\/nucleos(t)ide reverse transcriptase inhibitor-based second-line antiretroviral therapy for the treatment of human immunodeficiency virus type 1 infection in Sub-Saharan Africa: a systematic review and meta-analysis","volume":"66","author":"Stockdale","year":"2018","journal-title":"Clin Infect Dis"},{"key":"R32-20250504","first-page":"111","article-title":"2019 update of the drug resistance mutations in HIV-1","volume":"27","author":"Wensing","year":"2019","journal-title":"Top Antivir Med"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(97)03380-1","article-title":"HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial","volume":"350","author":"Brun-V\u00e9zinet","year":"1997","journal-title":"Lancet"},{"key":"R34-20250504","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1097\/00002030-200012220-00009","article-title":"Loss of antiretroviral drug susceptibility at low viral load during early virological failure in treatment-experienced patients","volume":"14","author":"Parkin","year":"2000","journal-title":"Aids"},{"key":"R35-20250504","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/01.qai.0000174929.87015.d6","article-title":"HIV-1 drug resistance evolution among patients on potent combination antiretroviral therapy with detectable viremia","volume":"40","author":"Napravnik","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R36-20250504","doi-asserted-by":"crossref","first-page":"01","DOI":"10.1371\/journal.pone.0012598","article-title":"Estimating the impact of plasma HIV-1 rna reductions on heterosexual HIV-1 transmission risk","volume":"5","author":"Lingappa","year":"2010","journal-title":"PLoS One"},{"key":"R37-20250504","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1093\/jac\/dks310","article-title":"Characterization of HIV-1 antiretroviral drug resistance after second-line treatment failure in Mali, a limited-resources setting","volume":"67","author":"Maiga","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"R38-20250504","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1097\/01.aids.0000131358.29586.6b","article-title":"Evolution of resistance to drugs in HIV-1-infected patients failing antiretroviral therapy","volume":"18","author":"Kantor","year":"2004","journal-title":"Aids"},{"key":"R39-20250504","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/QAD.0b013e32805e8764","article-title":"Triple-class antiretroviral drug resistance: risk and predictors among HIV-1-infected patients","volume":"21","author":"Napravnik","year":"2007","journal-title":"Aids"},{"key":"R40-20250504","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S1550-8579(07)80025-8","article-title":"Antiretroviral pharmacokinetic profile: a review of sex differences","volume":"4","author":"Ofotokun","year":"2007","journal-title":"Gend Med"},{"key":"R41-20250504","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1146\/annurev.pharmtox.44.101802.121453","article-title":"Sex differences in pharmacokinetics and pharmacodynamics","volume":"44","author":"Gandhi","year":"2004","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"R42-20250504","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1089\/aid.2011.0089","article-title":"HIV type 1 subtype surveillance in central Kenya","volume":"28","author":"Kageha","year":"2012","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R43-20250504","doi-asserted-by":"crossref","first-page":"19262","DOI":"10.7448\/IAS.17.1.19262","article-title":"HIV diversity and drug resistance from plasma and non-plasma analytes in a large treatment programme in western Kenya","volume":"17","author":"Kantor","year":"2014","journal-title":"J Int AIDS Soc"},{"key":"R44-20250504","doi-asserted-by":"crossref","first-page":"04","DOI":"10.1186\/1742-6405-6-12","article-title":"Effectiveness of antiretroviral therapy and development of drug resistance in HIV-1 infected patients in Mombasa, Kenya","volume":"6","author":"Steegen","year":"2009","journal-title":"AIDS Res Ther"},{"key":"R45-20250504","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1089\/aid.2009.0007","article-title":"HIV type 1 subtype diversity and drug resistance among HIV Type 1-infected kenyan patients initiating antiretroviral therapy","volume":"25","author":"Lihana","year":"2009","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R46-20250504","doi-asserted-by":"crossref","first-page":"e3191","DOI":"10.1371\/journal.pone.0003191","article-title":"Genetic analysis of HIV-1 subtypes in Nairobi, Kenya","volume":"3","author":"Khoja","year":"2008","journal-title":"PLoS One"},{"key":"R47-20250504","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1093\/jac\/dky005","article-title":"Primary resistance to integrase strand transfer inhibitors in patients infected with diverse HIV-1 subtypes in sub-Saharan Africa","volume":"73","author":"Inzaule","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"R48-20250504","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1093\/cid\/cir686","article-title":"Antiretroviral therapy for HIV: do subtypes matter?","volume":"53","author":"Gatell","year":"2011","journal-title":"Clin Infect Dis"},{"key":"R49-20250504","doi-asserted-by":"crossref","first-page":"a007161","DOI":"10.1101\/cshperspect.a007161","article-title":"HIV-1 antiretroviral drug therapy","volume":"2","author":"Arts","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"R50-20250504","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1177\/135965350601100617","article-title":"HIV-1 subtypes and response to combination antiretroviral therapy in Europe","volume":"11","author":"Bannister","year":"2006","journal-title":"Antivir Ther"},{"key":"R51-20250504","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1086\/598502","article-title":"Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy","volume":"48","author":"Geretti","year":"2009","journal-title":"Clin Infect Dis"},{"key":"R52-20250504","first-page":"503","article-title":"Mortality of treated HIV-1 positive individuals according to viral subtype in Europe and Canada: Collaborative cohort analysis","volume":"30","author":"May","year":"2016","journal-title":"Aids"},{"key":"R53-20250504","doi-asserted-by":"crossref","first-page":"e0131994","DOI":"10.1371\/journal.pone.0131994","article-title":"Development of nevirapine resistance in children exposed to the prevention of mother-to-child HIV-1 transmission programme in Maputo, Mozambique","volume":"10","author":"Antunes","year":"2015","journal-title":"PLoS One"},{"key":"R54-20250504","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1086\/430764","article-title":"Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP","volume":"192","author":"Eshleman","year":"2005","journal-title":"J Infect Dis"},{"key":"R55-20250504","doi-asserted-by":"crossref","first-page":"01","DOI":"10.1186\/s12889-020-09121-6","article-title":"HIV epidemic and cascade of care in 12 east African rural fishing communities: Results from a population-based survey in Uganda","volume":"20","author":"Burgos-Soto","year":"2020","journal-title":"BMC Public Health"},{"key":"R56-20250504","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1097\/OLQ.0b013e31818318c0","article-title":"HIV and sexual behavior among young people: the South African paradox","volume":"35","author":"Pettifor","year":"2008","journal-title":"Sex Transm Dis"},{"key":"R57-20250504","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1016\/S0140-6736(02)08780-9","article-title":"Sexual mixing patterns and sex-differentials in teenage exposure to HIV infection in rural Zimbabwe","volume":"359","author":"Gregson","year":"2002","journal-title":"Lancet"},{"key":"R58-20250504","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.jadohealth.2020.09.027","article-title":"Seeking a \u201cSponyo\u201d: insights into motivations and risks around intergenerational transactional sex among adolescent boys and girls in Kenya","volume":"68","author":"Zamudio-Haas","year":"2021","journal-title":"J Adolesc Heal"},{"key":"R59-20250504","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.3201\/eid1011.040252","article-title":"Sexual power and HIV risk, South Africa","volume":"10","author":"Pettifor","year":"2004","journal-title":"Emerg Infect Dis"},{"key":"R60-20250504","doi-asserted-by":"crossref","first-page":"347","DOI":"10.3390\/v3040347","article-title":"Clinical management of HIV drug resistance","volume":"3","author":"Cortez","year":"2011","journal-title":"Viruses"},{"key":"R61-20250504","doi-asserted-by":"crossref","first-page":"15035","DOI":"10.1038\/nrdp.2015.35","article-title":"HIV infection","volume":"1","author":"Deeks","year":"2015","journal-title":"Nat Rev Dis Prim"},{"key":"R62-20250504","doi-asserted-by":"crossref","first-page":"01","DOI":"10.1371\/journal.pone.0249813","article-title":"Intimate partner violence is a barrier to antiretroviral therapy adherence among HIV-positive women: Evidence from government facilities in Kenya","volume":"16","author":"Biomndo","year":"2021","journal-title":"PLoS One"},{"key":"R63-20250504","first-page":"658","article-title":"Hunger, waiting time and transport costs: time to confront challenges to ART adherence in Africa","volume":"19","author":"Hardon","year":"2007","journal-title":"AIDS Care - Psychol Socio-Medical Asp AIDS\/HIV"},{"key":"R64-20250504","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1086\/340215","article-title":"Evolution of human immunodeficiency virus type 1 populations after resumption of therapy following treatment interruption and shift in resistance genotype","volume":"185","author":"Izopet","year":"2002","journal-title":"J Infect Dis"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000027460","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T06:32:29Z","timestamp":1746340349000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000027460"}},"subtitle":["A cross-sectional study"],"short-title":[],"issued":{"date-parts":[[2021,10,8]]},"references-count":60,"journal-issue":{"issue":"40","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000027460","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,8]]},"assertion":[{"value":"2021-06-14","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-20","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}